Chotirat Nakaranurack BCP, Watsa Charoenwaiyachet, Benjabhorn Weeraphon, Kanthicha Pasompram, Pattama Torvorapanit , Watsamon Jantarabenjakul, Gompol Suwanpimolkul, Leilani Paitoonpong, Opass Putcharoen 1
Abstract : New therapies are being studied for COVID-19. Favipiravir and remdesivir have been used for treatment. There are limited reports of adverse drug reactions (ADRs) in Thai patients. A retrospective study was conducted at King Chulalongkorn Memorial hospital in hospitalized COVID-19 patients who received favipiravir or Remdesivir. From January to February 2021, 60 patients were enrolled. Twelve and 20 patients received remdesivir and favipiravir for treatment, respectively. Nineteen patients were male. Their mean (SD) age and BMI were 48.5 (15) years and 28.1 (8) kg/m2. The common comorbidity was hypertension. Most ADRs are mild and no need for drug discontinuation. Among remdesivir group, our study found transaminitis ( alanine aminotransferase > 40 U/L ) 5 cases (41.7%), hemoglobin reduction and less than 11g/dL 3 cases ( 25 %). There were no reports for infusion related reaction and QT prolongation. Among Favipiravir group, our study found hemoglobin reduction and less than 11g/dL 1 cases (5%), transaminitis (alanine aminotransferase > 40 U/L ) 2 cases (10%). There were no reported for vomiting, diarrhea, arthralgia and QT prolongation. In conclusion, no serious ADRs was found among our patients. However both antiviral agents are very new, more study about ADRs data are required.